Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stakeholders Urge CMS To Remove Conditions On Coverage Of PET For Cancer

This article was originally published in The Gray Sheet

Executive Summary

The National Oncologic PET Registry Working Group has strong support from industry and other stakeholders in its request that CMS end data collection requirements for coverage of positron emission tomography scans for cancer

You may also be interested in...



MedCAC Says PET Data Is Too Weak To Remove Registry Requirement

CMS should maintain its data collection requirements for coverage of positron emission tomography for nine cancers, because the evidence linking PET to improved outcomes is still weak, the Medicare Evidence Development and Coverage Advisory Committee concluded at its Aug. 20 meeting

MedCAC Says PET Data Is Too Weak To Remove Registry Requirement

CMS should maintain its data collection requirements for coverage of positron emission tomography for nine cancers, because the evidence linking PET to improved outcomes is still weak, the Medicare Evidence Development and Coverage Advisory Committee concluded at its Aug. 20 meeting

MedCAC for PET

Medicare Evidence Development and Coverage Advisory Committee will meet Aug. 20 in Baltimore to give CMS feedback on its open national coverage analysis of positron emission tomography scans. The agency is considering removing the data collection requirements it put in place in 2005 as conditions of coverage for PET scans for diagnosis, staging and restaging of brain, ovarian, prostate and certain other cancers (1"The Gray Sheet" June 2, 2008, p. 11). The scheduled MedCAC meeting pushes CMS' deadline for a proposed decision back two months to Jan. 10, 2009

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel